TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 548840
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg twice a day)
Study: 548840
Drug: Adrenalin (epinephrine
Normalized name: EPINEPHRINE 16 ug in 1 mL INTRAVENOUS INJECTION [Adrenalin (epinephrine in sodium chloride)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalin (epinephrine eyedrops twice a day)
Study: 20446856
Drug: Tiotropium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium therapy
Study: 15592731
Drug: Modafinil 400
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400 mg/d
Study: 11106916
Drug: DHEA replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA replacement (50 mg/day for 6 months)
Study: 9322326
Drug: Differentiated, individual‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated, individual‐based treatment program
Study: 3019212
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg per day
Study: 3019212
Drug: Altizide 15
Normalized name: althiazide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Altizide 15 mg combined with Spironolactone 25 mg
Study: 10071518
Drug: diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: diphenhydramine 50 mg
Study: 16168682
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg glucosamine sulfate
Study: 16168682
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg glucosamine sulfate
Study: 16168682
Drug: 3,000 mg
Normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3,000 mg glucosamine sulfate
Study: 12211218
Drug: Ocular instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular instillation of carteolol (0.8 mg)
Study: 12211218
Drug: Nasal instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal instillation of carteolol (0.8 mg)
Study: 10770458
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (20 mg/kg body weight) as adjunct to neuroleptic medication
Study: 3520988
Drug: OKT3 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3 monoclonal antibody
Study: 14621840
Drug: ALG (antilymphocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALG (antilymphocyte globulin) polyclonal antibody
Study: 3909732
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered terbutaline sulphate (0.1 mg in 1 ml cellulose gel)
Study: 3909732
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered terbutaline sulphate (5-g medicated vaginal polymer ring containing 10% terbutaline sulphate)
Study: 3909732
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered terbutaline
Study: 23958607
Drug: Integrated body‐mind‐spirit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated body‐mind‐spirit group intervention (4 sessions, >3 hours each, once per week) + routine hospital treatment
Study: 23958607
Drug: Routine hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hospital treatment only
Study: 7961198
Drug: 500 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/L CaCO3
Study: 7961198
Drug: 200 mg/L
Normalized name: cimetidine in 0.9 % NaCl 1,200 mg/L INTRAVEN INTRAVENOUS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/L ofloxacin
Study: 7961198
Drug: 2000 mg/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg/L ciprofloxacin with 5000 mg/L CaCO3
Study: 7961198
Drug: 200 mg/L
Normalized name: cimetidine in 0.9 % NaCl 1,200 mg/L INTRAVEN INTRAVENOUS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/L ofloxacin with 5000 mg/L CaCO3
Study: 7961198
Drug: 400 mg/L
Normalized name: theophylline in dextrose 5 % 400 mg/L INTRAVEN INTRAVENOUS SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/L ciprofloxacin with 5000 mg/L CaCO3
Study: 2975595
Drug: Doxazosin 8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 8 mg daily
Study: 29892042
Drug: Exosomes from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exosomes from fasting morning plasma samples after 3 months of CPAP therapy (n=24)
Study: 26718897
Drug: Community-based educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based educational intervention led by lay health workers including monthly distribution of Iron and folic acid (IFA) supplements and five monthly counseling sessions.
Study: 26718897
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (control group) including distribution of IFA to mothers of anemic children without education and counseling support.
Study: 24077193
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural injections with lidocaine 0.5% preservative-free, 5 mL (Group I)
Study: 24077193
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural injections with 0.5% preservative-free lidocaine mixed with 1 mL or 6 mg of non-particulate betamethasone (Group II)
Study: 24077193
Drug: Cervical epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical epidural injections with lidocaine 0.5% preservative-free (Group I)
Study: 12450708
Drug: Flt3 ligand
Normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flt3 ligand (20 microg/kg, maximum 1500 microg) administered SQ every day for 1 week
Study: 2657199
Drug: Other glaucoma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other glaucoma drugs
Study: 25336703
Drug: Cisplatin ≤
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin ≤ 850 mg
Study: 18569006
Drug: 3.0 g
Normalized name: LACTIC ACID 23.0 g in 1 L TOPICAL SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g NS day(‐1) (high dose, HD)
Study: 18569006
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g NS day(‐1) (low dose, LD)
Study: 16222401
Drug: D-hormone serum
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-hormone serum concentrations (high)
Study: 16222401
Drug: D-hormone serum
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-hormone serum concentrations (low)
Study: 16222401
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake >= 512 mg/day
Study: 16222401
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake < 512 mg/day
Study: 16222401
Drug: D-hormone serum
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-hormone serum concentrations
Study: 10496143
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg) administered at 13:00 hr for 5 consecutive days during the late follicular and early luteal phases of the menstrual cycle.
Study: 7795515
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg atracurium
Study: 7795515
Drug: 0.07 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.07 mg/kg vecuronium
Study: 2385209
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ASS daily
Study: 2385209
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ASS daily
Study: 29953014
Drug: Ashwagandha extract
Normalized name: ashwagandha extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ashwagandha extract (daily supplement for 42 days)
Study: 29953014
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily supplement for 42 days)
Study: 27590106
Drug: Topical Dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Dexamethasone (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Study: 27590106
Drug: Topical Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tacrolimus (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Study: 27590106
Drug: Topical Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Tacrolimus
Study: 12117085
Drug: T/APAP 75/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/APAP 75/650 mg (2 tablets)
Study: 12117085
Drug: HC/APAP (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC/APAP (1 tablet)
Study: 12117085
Drug: T/APAP 75/650
Approvals — FDA: no, EMA: no, PMDA: no
Description: T/APAP 75/650 mg (1 tablet)
Study: 7518766
Drug: Intravenous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or intramuscular ceftriaxone 50 mg/kg/day for 2 days followed by oral cefetamet pivoxil 20 mg/kg/day in 2 divided doses to complete 7 days of treatment (arm A)
Study: 7518766
Drug: Ceftriaxone 50
Normalized name: ceftriaxone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 50 mg/kg/day for 1 day followed by 6 days' treatment with cefetamet pivoxil 20 mg/kg/day (arm B)
Study: 2923962
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 10 mg test tablets, 1 x 40 mg test tablet, 4 x 10 mg Inderal tablets, 40 mg of propranolol HCl in solution (Study I)
Study: 2923962
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 80 mg test tablet, 1 x 80 mg Inderal tablet, 80 mg of propranolol HCl in solution (Study II)
Study: 31212044
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment
Study: 31593484
Drug: FOLFOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil bolus 400 mg/m2 on day 1, fluorouracil infusion 2,400 mg/m2 for 46 hours)
Study: 31593484
Drug: FL (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FL (fluorouracil 380 mg/m2 and leucovorin 20 mg/m2)
Study: 25218876
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (100 mL before each dialysis session)
Study: 25218876
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (1,050 mg daily)
Study: 21793817
Drug: Nontraditional practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontraditional practice (problems presented in a nontraditional format, e.g., 17 = 9 + 8)
Study: 21793817
Drug: Traditional practice
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional practice (problems presented in the traditional 'operations on left side' format, e.g., 9 + 8 = 17)
Study: 8915800
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids
Study: 15305956
Drug: Short nitroglycerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short nitroglycerine test (15 minutes passive phase + 400 microg sublingual nitroglycerin for 15 minutes)
Study: 15305956
Drug: Conventional isoproterenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional isoproterenol protocol (30 minutes passive phase + 20 minutes drug-challenge phase)
Study: 8437633
Drug: HA-1A (Centoxin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A (Centoxin), a human anti-endotoxin monoclonal IgM antibody
Study: 30157880
Drug: Anakinra, self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra, self-administered daily by subcutaneous injection over 8 weeks
Study: 27125363
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy)
Study: 27125363
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Study: 27125363
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy) with discontinuation of tenofovir-DF
Study: 27125363
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus two NRTIs (triple-therapy) with discontinuation of abacavir
Study: 27125363
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus lamivudine (dual-therapy) and Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Study: 20398185
Drug: PK measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK measurements for dose tailoring of FVIII
Study: 10475187
Drug: Intra-arterial infusions
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusions of L-arginine
Study: 10475187
Drug: Intra-arterial infusions
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusions of sodium nitroprusside
Study: 27633636
Drug: Family-led rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-led rehabilitation intervention for stroke patients, details on dosage and duration not specified.
Study: 25056464
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone (group A, n=51)
Study: 22772417
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation management (treatment group)
Study: 20117625
Drug: Nonoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative therapy (control)
Study: 16836502
Drug: Benzyl benzoate
Normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzyl benzoate (BB) lotion for 5 days
Study: 2702160
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy by dental school assistants (experimental group)
Study: 4311188
Drug: Intravenous methylamphetamine
Normalized name: dimethylamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylamphetamine
Study: 4311188
Drug: Oral dexamphetamine
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamphetamine
Study: 3187466
Drug: Continuous ultrasound
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ultrasound treatment
Study: 28632555
Drug: Sham ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham ultrasound treatment
Study: 19857039
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (radiotherapy or radiochemotherapy)
Study: 15818076
Drug: Nonselective nonsteroidal
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonselective nonsteroidal anti‐inflammatory drug
Study: 11910256
Drug: Thioridazine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (200 mg, bid)
Study: 11910256
Drug: Risperidone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3 mg, bid)
Study: 11910256
Drug: Haloperidol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (7.5 mg, bid)
Study: 11910256
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three coadministered therapies
Study: 11910256
Drug: Quetiapine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine monotherapy transitioning to coadministration
Study: 11122797
Drug: Anthracyclines, platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracyclines, platinum compounds, and paclitaxel
Study: 11122797
Drug: Immunohistochemical determination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunohistochemical determination of tumor receptor status
Study: 11122797
Drug: Anti-HER2/neu monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HER2/neu monoclonal antibody
Study: 8669350
Drug: Conventional discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional discharge (CD) preparation
Study: 683909
Drug: Extra potassium
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra potassium supplements
Study: 27001804
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of PXVX0200 (approximately 5 × 10(8) CFU)
Study: 20829597
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine Daikenchuto (TJ‐100; 5.0 g) with distilled water (Group B)
Study: 17079360
Drug: Goldenseal (3210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goldenseal (3210 mg daily for 14 days)
Study: 17079360
Drug: Kava kava
Normalized name: Kava kava
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava kava (1227 mg daily for 14 days)
Study: 16221754
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg daily for 7 days)
Study: 16221754
Drug: Clarithromycin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (1000 mg daily for 7 days)
Study: 16244024
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion via 2 epidural catheters for postoperative analgesia (group E)
Study: 16244024
Drug: Intraoperative general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative general anesthesia and postoperative IV morphine analgesia (group G)
Study: 12107602
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg daily
Study: 10338217
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (GLN) 10 g three times daily
Study: 10338217
Drug: Glycine-control (GLY)
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine-control (GLY) 10 g three times daily
Study: 10338217
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (GLN)
Study: 10338217
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and parenteral glutamine (GLN)
Study: 8747034
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/day for 6 months
Study: 1903079
Drug: Dihydroergocryptine (DEK)
DrugBank: Dihydroergocryptine (DB13385)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergocryptine (DEK) at mean daily doses of approximately 40 mg (ranging from 15 to 60 mg)
Study: 7381028
Drug: Sulfinpyrazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (200 mg orally three times a day)
Study: 19540659
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity pulsed ultrasound (LIPUS) treatment
Study: 17440643
Drug: Losartan (L)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (L) 50 mg plus Hydrochlorothiazide (HCTZ) 12.5 mg titrated to L 100 mg plus HCTZ 25 mg
Study: 17440643
Drug: Losartan (L)
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan (L) and Hydrochlorothiazide (HCTZ)
Study: 17440643
Drug: Stepped-care (HCTZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care (HCTZ 12.5 mg plus Atenolol 50 mg)
Study: 15239726
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tryptase and histamine measurements
Study: 8250765
Drug: Buserelin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (900 micrograms/d administered intranasally)
Study: 8250765
Drug: Danazol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (400 mg/d p.o.)
Study: 3533825
Drug: Bendroflumethiazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (2.5 mg) + 573 mg potassium chloride 3 times a day
Study: 31788880
Drug: nano-curcumin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-curcumin (80 mg daily for 8 weeks)
Study: 27694598
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for type III fractures
Study: 22189524
Drug: Clindamycin or
Normalized name: clindamycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin or first-generation cephalosporin (IV for 2-4 days, then oral)
Study: 20965458
Drug: Overnight hospitalization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight hospitalization with 12-hour abciximab infusion
Study: 30789515
Drug: Sequential application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential application of 1,450-nm diode laser and 450-nm blue light
Study: 28301865
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and static ultrasound
Study: 28301865
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and diadynamic currents
Study: 20551220
Drug: Varenicline (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.25, 0.5, 1.0, 2.0 mg)
Study: 20551220
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 or 1.0 mg) twice daily
Study: 17255304
Drug: Sorafenib (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (in combination with IFN, bevacizumab, or temsirolimus)
Study: 15124757
Drug: IFNbeta‐1a 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 30 mcg IM once weekly
Study: 15124757
Drug: IFNbeta‐1a 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a 60 mcg IM once weekly
Study: 15124757
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of IFNbeta‐1a
Study: 11697022
Drug: Allicin-containing garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allicin-containing garlic supplement, one capsule daily for 12 weeks